MOTS-c, the mitochondrial-derived peptide, and what the rodent metabolic literature does and does not show

Key takeaways

• MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene, identified and characterized in the Lee 2015 Cell Metabolism paper as a peptide that promotes metabolic homeostasis and reduces obesity and insulin resistance in mice .
• The proposed mechanism involves AMPK activation and folate one-carbon metabolism, with downstream effects on glucose uptake and lipid handling in skeletal muscle. The pathway has been replicated across several independent rodent and cell-line studies .
• Circulating MOTS-c is detectable in human plasma and declines with age in cross-sectional descriptions. A small human PK/PD body of work exists but no large randomized human outcome trial has read out .
• MOTS-c is not FDA-approved. The FDA has flagged peptides marketed for research use among bulk substances with safety-risk concerns, and the Vial-grade product sold to the research community is not the same regulatory category as an approved drug .
• Community framing of MOTS-c as a settled 'mitochondrial longevity' or 'exercise mimetic' therapy outruns the published human data. The rodent metabolic-homeostasis program is the strongest part of the literature; broader human outcome claims remain unverified.

What MOTS-c is and where it comes from

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. The peptide is encoded by a small open reading frame embedded within the 12S ribosomal RNA gene of the mitochondrial genome. That genomic location is unusual: nearly all peptides in human physiology are encoded by the nuclear genome and imported into mitochondria as needed. A short list of peptides, including MOTS-c, humanin, and the SHLP family, are encoded inside the mitochondrial genome itself. They are collectively called mitochondrial-derived peptides, or MDPs .

The mature MOTS-c peptide is 16 amino acids long. Its translation is thought to involve cytoplasmic ribosomes acting on transcripts that escape the mitochondrion, rather than the mitochondrial translation apparatus that produces the canonical 13 oxidative-phosphorylation subunits. The biological consequence is that the peptide can act both inside the mitochondrion and at distant tissues, including skeletal muscle and adipose tissue, after secretion into circulation .

Lee 2015: the foundational rodent metabolic program

Lee C, Zeng J, Drew BG, et al. published The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance in Cell Metabolism in 2015 (PMID 25738459). The paper used a combination of in vitro myocyte work and in vivo mouse studies to characterize the peptide's metabolic effects .

The headline rodent findings, as reported in the paper, were that intraperitoneally administered MOTS-c improved insulin sensitivity in diet-induced obese mice, reduced age-related insulin resistance in older mice, and increased glucose uptake in skeletal muscle. Mechanistically, the authors implicated AMPK activation and folate one-carbon metabolism, with downstream effects on de novo purine synthesis and methionine handling. The proposed pathway integrated MOTS-c into a broader picture of mitochondrial signaling to skeletal muscle.

What the human literature actually says

Human MOTS-c work falls into two categories. The first is observational: cross-sectional and longitudinal measurement of circulating MOTS-c in plasma or serum samples. Published descriptions report that detectable MOTS-c circulates in human plasma at low picogram-per-milliliter concentrations, that levels decline with age, and that levels rise acutely after exercise in some cohorts. These observations support the biological plausibility of a circulating MDP system in humans but do not establish a therapeutic effect of exogenous administration .

The second category is interventional. A small body of published pharmacokinetic and pharmacodynamic descriptions of exogenously administered MOTS-c exists, primarily in early-stage research-vial contexts. There is no large randomized placebo-controlled human outcome trial of MOTS-c administration in obesity, insulin resistance, sarcopenia, or longevity endpoints at the time of writing. ClinicalTrials.gov lists a small number of registered protocols touching MOTS-c measurement or related MDP biology, but no late-phase efficacy trial has read out a settled human protocol .

• Yes: circulating MOTS-c is measurable in human plasma and tracks roughly with age and acute exercise in published cohorts.
• Yes: the rodent metabolic-homeostasis program is reproducible across multiple labs.
• No: there is no FDA-approved MOTS-c product.
• No: there is no published large randomized human outcome trial of exogenous MOTS-c administration with a clinical endpoint.
• No: rodent dose ranges and frequency schedules do not transfer to human protocols without dedicated PK work.

AMPK and the exercise-mimetic claim

MOTS-c is frequently described in community contexts as an exercise mimetic, on the basis that AMPK activation is one of the well-known downstream consequences of contracting skeletal muscle and that exogenous MOTS-c activates AMPK in rodent muscle preparations. The mechanistic linkage is reasonable; the claim that injecting MOTS-c replaces the effect of structured exercise is not supported by the published human evidence .

Exercise produces a coordinated multi-pathway response: AMPK activation alongside PGC-1-alpha-mediated mitochondrial biogenesis, capillary growth, satellite-cell proliferation, mechanotransduction, and central cardiovascular adaptation. Activating one node of that network with a single peptide is not the same as moving the whole network. The honest framing is that MOTS-c is a candidate metabolic signaling peptide with rodent evidence for AMPK activation, not a documented substitute for training.

Longevity framing and the broader MDP family

The broader mitochondrial-derived peptide family includes humanin, the SHLP series (small humanin-like peptides 1 through 6), and MOTS-c. Humanin has a longer literature in neuroprotection and cytoprotection contexts, and several MDP family members have been associated with longevity endpoints in human cohort studies. The argument for MOTS-c as a longevity intervention typically rests on this family-level pattern plus the Lee 2015 rodent metabolic data .

That family-level pattern does not translate cleanly into a per-peptide dosing recommendation. The published human work in MDPs is still descriptive. The most rigorous current statement is that MDPs are part of mitochondrial signaling biology, that MOTS-c is the best-characterized member in metabolic contexts, and that a settled human therapeutic protocol has not been established. Article-quality coverage of MOTS-c therefore lands on mechanism and rodent evidence, not on a recommended human regimen.

Regulatory and research-vial context

There is no FDA-approved MOTS-c drug label. The product sold to the research community as a lyophilized peptide vial is not the regulatory equivalent of an approved drug, and the FDA's posture on peptide bulk substances flags identity, purity, and safety concerns for community-sourced peptide preparations more generally .

For research and educational purposes only. Not medical advice. Decisions about any mitochondrial-derived peptide therapy should involve a qualified clinician who can review individual context and weigh the gap between rodent mechanism evidence and human outcome evidence.

Editorial summary

MOTS-c is the best-characterized member of the mitochondrial-derived peptide family, and the Lee 2015 Cell Metabolism program is the strongest part of its evidence base. The rodent metabolic-homeostasis findings are reproducible; the proposed AMPK mechanism is biologically reasonable; the family-level role in mitochondrial signaling is well established. The honest gap is the human outcome evidence. Until a randomized human trial reads out, the right framing for MOTS-c is mechanism-rich and outcome-uncertain.

Related tools

• Body-recomp simulator overview - Public overview of the Pro body-recomposition simulator.
• Protocol builder overview - Public overview of the Pro protocol builder.
• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.